Skip to content

Innovating for Universal Health

About TaiU

Taiwan Universe BioMedicine (TaiU) is a clinical-stage ready biopharmaceutical innovator specializing in next-generation vaccine platforms. A high-tech spin-off from Taiwan’s premier national health research institute, TaiU is led by Dr. Min-Shi Lee (Oxford Ph.D.), a vaccine pioneer and former core developer of the US FDA-approved FluMist vaccine.

Driven by world-class translational science, TaiU bridges the gap between disruptive early-stage antigen design and scalable commercial manufacturing.

Technology

Our Core Asset Portfolio

Driven by world-class translational science, TaiU bridges the gap between disruptive early-stage antigen design and scalable commercial manufacturing.

TaiU is open to strategic licensing, co-development, and manufacturing scale-up partnerships with global biopharmaceutical leaders. For clinical data packages or technical inquiries, please contact us.

Influenza vaccines Development

1st generation
Egg-based inactivated Vaccines

• Takes 20 weeks to produce
• Need live virus
• Mutations in HA

2nd generation
Cell-based inactivated Vaccines

• Takes 16 weeks to produce
• Need live virus
• Few mutations in HA

3rd generation
Recombinant Protein Vaccines

• Reduce to only 12 weeks production
• No mutations in HA
• No live viruses
• Ready for emerging viruses (novel influenza, etc.)

Market Share %

Egg-based inactivated Vaccines

~85%

Cell-based inactivated Vaccines

~10%

Recombinant Protein Vaccines

~5% subunit HA (rHA, Flublok, too expensive)

Current Recombinant Protein flu Vaccine Development

Company Platforms HA antigen doses

NHRI Spin-off

VLP using Insect cells (Sf21 and Hi5)

15-30 µg/strain

Sanofi*
rHA using Insect cell (Sf9)
45 µg/strain
Medicago (bankruptcy in 2023)
VLP using plant (tobacco plant)
30 µg/strain
Novavax
rHA using Insect cell (Sf9)
60 µg/strain with adjuvant
Contact Us

Taiwan Universe BioMedicine Inc. 2026 © All Rights Reserved.